cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 New trial data on CagriSema
New trial data on CagriSema 23% weight loss at 84 weeks in the RE DEFINE 4 trial. CagriSema pairs semaglutide with cagrilintide, an amylin analogue. Amylin is a pancreatic hormone that slows Novo Nordisk's Cagrilintide shows promising weight loss in REDEFINE 1 sub analysis, unveiled at EASD 2025 Pharmacally Ozempic potentially dethroned by CagriSema, but weight loss still wins Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace
Pay in 4 interest-free payments of $5.03 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12


